Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1988-08

AUTHORS

Andreas Supersaxo, Wayne Hein, Harald Gallati, Hans Steffen

ABSTRACT

The effect of different parenteral administration routes (i.d., s.c., i.v.), infusion rates, and albumin contents of the drug vehicle on the cumulative recovery of recombinant human interferon alpha-2a (rIFN alpha-2a) in lymph and on its concentration in blood and lymph was determined in sheep. Blood samples were withdrawn from a jugular vein catheter and lymph was collected from a cannulated efferent popliteal lymphatic duct. The concentration of rIFN alpha-2a in lymph and blood plasma samples was measured by an enzyme immunoassay. Following i.v. infusion of 2 x 10(7) U of rIFN alpha-2a, the peak concentrations measured in blood plasma and lymph, respectively, were 8250 and 14 U/ml. The concentration measured in lymph after i.d. or s.c. administration of the same dose was about 10(5) times higher (peak concentration, 3.1 x 10(6) U/ml), while blood plasma levels remained low (peak concentration, 315 U/ml). The cumulative recovery of rIFN alpha-2a in lymph following i.d. or s.c. administration was 59.2 +/- 7% (mean +/- SD; N = 8) and was affected neither by the infusion rate nor by the coadministration of albumin. Our data indicate that following i.d. or s.c. administration, rIFN alpha-2a (MW 19,000) is absorbed mainly by the lymphatics. This results in high levels of rIFN alpha-2a in the lymph which drains from the application site to the regional lymph nodes. The knowledge gained in this investigation may help to improve the mode of administration and therapeutic efficacy of protein drugs whose targets are lymphoid cells. More... »

PAGES

472-476

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1015957022073

DOI

http://dx.doi.org/10.1023/a:1015957022073

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045641677

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/3244653


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Absorption", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intradermal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Subcutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon Type I", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymph", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoid Tissue", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serum Albumin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sheep", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Pharmaceutical Research/Preclinical Development, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Supersaxo", 
        "givenName": "Andreas", 
        "id": "sg:person.01263702367.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263702367.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Basilea Pharmaceutica (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.418234.8", 
          "name": [
            "Basel Institute for Immunology, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hein", 
        "givenName": "Wayne", 
        "id": "sg:person.0753747224.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753747224.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Central Research Units, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gallati", 
        "givenName": "Harald", 
        "id": "sg:person.01200100054.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200100054.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Pharmaceutical Research/Preclinical Development, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steffen", 
        "givenName": "Hans", 
        "id": "sg:person.01247014417.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247014417.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0306-3623(86)90189-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001818489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0306-3623(86)90189-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001818489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/bpb1978.7.59", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005279663"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0306-3623(86)90017-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005628349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0306-3623(86)90017-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005628349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1016377114477", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008981868", 
          "https://doi.org/10.1023/a:1016377114477"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/bpb1978.8.206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011665258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19860415)57:8+<1648::aid-cncr2820571303>3.0.co;2-o", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012261851"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02118644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012918196", 
          "https://doi.org/10.1007/bf02118644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02118644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012918196", 
          "https://doi.org/10.1007/bf02118644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0167-5699(85)90159-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017875411"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1113/expphysiol.1962.sp001620", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031555789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1084/jem.121.6.901", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040893216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0003-9861(83)90118-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043004064"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(86)90168-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044279461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(86)90168-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044279461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1016349605061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045321048", 
          "https://doi.org/10.1023/a:1016349605061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/cdd.1984.1.337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059243547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078798623", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081946813", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1988-08", 
    "datePublishedReg": "1988-08-01", 
    "description": "The effect of different parenteral administration routes (i.d., s.c., i.v.), infusion rates, and albumin contents of the drug vehicle on the cumulative recovery of recombinant human interferon alpha-2a (rIFN alpha-2a) in lymph and on its concentration in blood and lymph was determined in sheep. Blood samples were withdrawn from a jugular vein catheter and lymph was collected from a cannulated efferent popliteal lymphatic duct. The concentration of rIFN alpha-2a in lymph and blood plasma samples was measured by an enzyme immunoassay. Following i.v. infusion of 2 x 10(7) U of rIFN alpha-2a, the peak concentrations measured in blood plasma and lymph, respectively, were 8250 and 14 U/ml. The concentration measured in lymph after i.d. or s.c. administration of the same dose was about 10(5) times higher (peak concentration, 3.1 x 10(6) U/ml), while blood plasma levels remained low (peak concentration, 315 U/ml). The cumulative recovery of rIFN alpha-2a in lymph following i.d. or s.c. administration was 59.2 +/- 7% (mean +/- SD; N = 8) and was affected neither by the infusion rate nor by the coadministration of albumin. Our data indicate that following i.d. or s.c. administration, rIFN alpha-2a (MW 19,000) is absorbed mainly by the lymphatics. This results in high levels of rIFN alpha-2a in the lymph which drains from the application site to the regional lymph nodes. The knowledge gained in this investigation may help to improve the mode of administration and therapeutic efficacy of protein drugs whose targets are lymphoid cells.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1015957022073", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094644", 
        "issn": [
          "0724-8741", 
          "1573-904X"
        ], 
        "name": "Pharmaceutical Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "name": "Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application", 
    "pagination": "472-476", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d969a07ad3ec981202dfe1f1ff7baffc056bddb3e9abb6741cbb81cb9d3c9871"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "3244653"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8406521"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1015957022073"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045641677"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1015957022073", 
      "https://app.dimensions.ai/details/publication/pub.1045641677"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T01:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000507.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023/A:1015957022073"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1015957022073'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1015957022073'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1015957022073'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1015957022073'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      21 PREDICATES      60 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1015957022073 schema:about N030188cb233e4d96aac902b5f2ff807a
2 N29bcd05b858c4908961660c878938b7c
3 N356111275e9648e0b342c9fb8ed7f325
4 N3a5a52bcd0f64fd78b6c15c8be2cdb1e
5 N577e5172d1d04650a2212b7cbc2c61e1
6 N59fe27138dbd4746a1d0d38a2506043a
7 N66050b3ac18c4a2795ddd4e0623f4f94
8 N7f9f6970d9e443638becb8ea91547465
9 N96de1c9771af48f493ac572ece06ea9e
10 Nb22b71317bd746bab4d481bb823de1d2
11 Nd21cd5f4dc614bf7a77e012164c919d5
12 Nd25e3f6752ed4cbd91c2284365eb360e
13 Nd82af0a15f044313aee0787e39d0da3a
14 Ne737d3c411714a959fab96ef9a870f62
15 Nf4bdf6c6db9f4dabaa8c1b32dcfcc67d
16 anzsrc-for:11
17 anzsrc-for:1102
18 schema:author N1795ea95a17b421aa1596ee350d9bdd9
19 schema:citation sg:pub.10.1007/bf02118644
20 sg:pub.10.1023/a:1016349605061
21 sg:pub.10.1023/a:1016377114477
22 https://app.dimensions.ai/details/publication/pub.1078798623
23 https://app.dimensions.ai/details/publication/pub.1081946813
24 https://doi.org/10.1002/1097-0142(19860415)57:8+<1648::aid-cncr2820571303>3.0.co;2-o
25 https://doi.org/10.1016/0003-9861(83)90118-2
26 https://doi.org/10.1016/0167-5699(85)90159-8
27 https://doi.org/10.1016/0306-3623(86)90017-0
28 https://doi.org/10.1016/0306-3623(86)90189-8
29 https://doi.org/10.1016/0378-5173(86)90168-7
30 https://doi.org/10.1084/jem.121.6.901
31 https://doi.org/10.1089/cdd.1984.1.337
32 https://doi.org/10.1113/expphysiol.1962.sp001620
33 https://doi.org/10.1248/bpb1978.7.59
34 https://doi.org/10.1248/bpb1978.8.206
35 schema:datePublished 1988-08
36 schema:datePublishedReg 1988-08-01
37 schema:description The effect of different parenteral administration routes (i.d., s.c., i.v.), infusion rates, and albumin contents of the drug vehicle on the cumulative recovery of recombinant human interferon alpha-2a (rIFN alpha-2a) in lymph and on its concentration in blood and lymph was determined in sheep. Blood samples were withdrawn from a jugular vein catheter and lymph was collected from a cannulated efferent popliteal lymphatic duct. The concentration of rIFN alpha-2a in lymph and blood plasma samples was measured by an enzyme immunoassay. Following i.v. infusion of 2 x 10(7) U of rIFN alpha-2a, the peak concentrations measured in blood plasma and lymph, respectively, were 8250 and 14 U/ml. The concentration measured in lymph after i.d. or s.c. administration of the same dose was about 10(5) times higher (peak concentration, 3.1 x 10(6) U/ml), while blood plasma levels remained low (peak concentration, 315 U/ml). The cumulative recovery of rIFN alpha-2a in lymph following i.d. or s.c. administration was 59.2 +/- 7% (mean +/- SD; N = 8) and was affected neither by the infusion rate nor by the coadministration of albumin. Our data indicate that following i.d. or s.c. administration, rIFN alpha-2a (MW 19,000) is absorbed mainly by the lymphatics. This results in high levels of rIFN alpha-2a in the lymph which drains from the application site to the regional lymph nodes. The knowledge gained in this investigation may help to improve the mode of administration and therapeutic efficacy of protein drugs whose targets are lymphoid cells.
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree false
41 schema:isPartOf Nddeaa9fbc3e54560a2ab263c8f8a88ed
42 Nf24cf50f717145cdae4ea4881a3ee447
43 sg:journal.1094644
44 schema:name Recombinant Human Interferon Alpha-2a: Delivery to Lymphoid Tissue by Selected Modes of Application
45 schema:pagination 472-476
46 schema:productId N00fa3c0581574a409f301beb88a51b0e
47 N6e5abae872eb4fa6b7fab8a40f611727
48 N7383faa0c64147c19dcee99af5ffa339
49 N7f2e97a85b91499894e869b9dee64b26
50 N9d1f333cbd504b059a7e4cde881f4c00
51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045641677
52 https://doi.org/10.1023/a:1015957022073
53 schema:sdDatePublished 2019-04-11T01:59
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher Nbb4f6d2319804fae81445f67000a8780
56 schema:url http://link.springer.com/10.1023/A:1015957022073
57 sgo:license sg:explorer/license/
58 sgo:sdDataset articles
59 rdf:type schema:ScholarlyArticle
60 N00fa3c0581574a409f301beb88a51b0e schema:name readcube_id
61 schema:value d969a07ad3ec981202dfe1f1ff7baffc056bddb3e9abb6741cbb81cb9d3c9871
62 rdf:type schema:PropertyValue
63 N030188cb233e4d96aac902b5f2ff807a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Injections, Intradermal
65 rdf:type schema:DefinedTerm
66 N1795ea95a17b421aa1596ee350d9bdd9 rdf:first sg:person.01263702367.82
67 rdf:rest N7544d56872e24822914e71cf0a93c8d8
68 N29bcd05b858c4908961660c878938b7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Infusions, Intravenous
70 rdf:type schema:DefinedTerm
71 N356111275e9648e0b342c9fb8ed7f325 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Injections, Subcutaneous
73 rdf:type schema:DefinedTerm
74 N3a5a52bcd0f64fd78b6c15c8be2cdb1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Sheep
76 rdf:type schema:DefinedTerm
77 N577e5172d1d04650a2212b7cbc2c61e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Humans
79 rdf:type schema:DefinedTerm
80 N59fe27138dbd4746a1d0d38a2506043a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Interferon Type I
82 rdf:type schema:DefinedTerm
83 N66050b3ac18c4a2795ddd4e0623f4f94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Absorption
85 rdf:type schema:DefinedTerm
86 N6e5abae872eb4fa6b7fab8a40f611727 schema:name pubmed_id
87 schema:value 3244653
88 rdf:type schema:PropertyValue
89 N7383faa0c64147c19dcee99af5ffa339 schema:name doi
90 schema:value 10.1023/a:1015957022073
91 rdf:type schema:PropertyValue
92 N7544d56872e24822914e71cf0a93c8d8 rdf:first sg:person.0753747224.17
93 rdf:rest N8385c3c19ff346d582ac31ec187f28fb
94 N7f2e97a85b91499894e869b9dee64b26 schema:name dimensions_id
95 schema:value pub.1045641677
96 rdf:type schema:PropertyValue
97 N7f9f6970d9e443638becb8ea91547465 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Recombinant Proteins
99 rdf:type schema:DefinedTerm
100 N8385c3c19ff346d582ac31ec187f28fb rdf:first sg:person.01200100054.05
101 rdf:rest Nfc905ffe8324485191017f1491f800d7
102 N96de1c9771af48f493ac572ece06ea9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Interferon-alpha
104 rdf:type schema:DefinedTerm
105 N9d1f333cbd504b059a7e4cde881f4c00 schema:name nlm_unique_id
106 schema:value 8406521
107 rdf:type schema:PropertyValue
108 Nb22b71317bd746bab4d481bb823de1d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Serum Albumin
110 rdf:type schema:DefinedTerm
111 Nbb4f6d2319804fae81445f67000a8780 schema:name Springer Nature - SN SciGraph project
112 rdf:type schema:Organization
113 Nd21cd5f4dc614bf7a77e012164c919d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Female
115 rdf:type schema:DefinedTerm
116 Nd25e3f6752ed4cbd91c2284365eb360e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Lymphoid Tissue
118 rdf:type schema:DefinedTerm
119 Nd82af0a15f044313aee0787e39d0da3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Time Factors
121 rdf:type schema:DefinedTerm
122 Nddeaa9fbc3e54560a2ab263c8f8a88ed schema:volumeNumber 5
123 rdf:type schema:PublicationVolume
124 Ne737d3c411714a959fab96ef9a870f62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Animals
126 rdf:type schema:DefinedTerm
127 Nf24cf50f717145cdae4ea4881a3ee447 schema:issueNumber 8
128 rdf:type schema:PublicationIssue
129 Nf4bdf6c6db9f4dabaa8c1b32dcfcc67d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Lymph
131 rdf:type schema:DefinedTerm
132 Nfc905ffe8324485191017f1491f800d7 rdf:first sg:person.01247014417.99
133 rdf:rest rdf:nil
134 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
135 schema:name Medical and Health Sciences
136 rdf:type schema:DefinedTerm
137 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
138 schema:name Cardiorespiratory Medicine and Haematology
139 rdf:type schema:DefinedTerm
140 sg:journal.1094644 schema:issn 0724-8741
141 1573-904X
142 schema:name Pharmaceutical Research
143 rdf:type schema:Periodical
144 sg:person.01200100054.05 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
145 schema:familyName Gallati
146 schema:givenName Harald
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200100054.05
148 rdf:type schema:Person
149 sg:person.01247014417.99 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
150 schema:familyName Steffen
151 schema:givenName Hans
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247014417.99
153 rdf:type schema:Person
154 sg:person.01263702367.82 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
155 schema:familyName Supersaxo
156 schema:givenName Andreas
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263702367.82
158 rdf:type schema:Person
159 sg:person.0753747224.17 schema:affiliation https://www.grid.ac/institutes/grid.418234.8
160 schema:familyName Hein
161 schema:givenName Wayne
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753747224.17
163 rdf:type schema:Person
164 sg:pub.10.1007/bf02118644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012918196
165 https://doi.org/10.1007/bf02118644
166 rdf:type schema:CreativeWork
167 sg:pub.10.1023/a:1016349605061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045321048
168 https://doi.org/10.1023/a:1016349605061
169 rdf:type schema:CreativeWork
170 sg:pub.10.1023/a:1016377114477 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008981868
171 https://doi.org/10.1023/a:1016377114477
172 rdf:type schema:CreativeWork
173 https://app.dimensions.ai/details/publication/pub.1078798623 schema:CreativeWork
174 https://app.dimensions.ai/details/publication/pub.1081946813 schema:CreativeWork
175 https://doi.org/10.1002/1097-0142(19860415)57:8+<1648::aid-cncr2820571303>3.0.co;2-o schema:sameAs https://app.dimensions.ai/details/publication/pub.1012261851
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/0003-9861(83)90118-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043004064
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/0167-5699(85)90159-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017875411
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/0306-3623(86)90017-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005628349
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/0306-3623(86)90189-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001818489
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/0378-5173(86)90168-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044279461
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1084/jem.121.6.901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040893216
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1089/cdd.1984.1.337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059243547
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1113/expphysiol.1962.sp001620 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031555789
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1248/bpb1978.7.59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005279663
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1248/bpb1978.8.206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011665258
196 rdf:type schema:CreativeWork
197 https://www.grid.ac/institutes/grid.417570.0 schema:alternateName Roche (Switzerland)
198 schema:name Central Research Units, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland
199 Pharmaceutical Research/Preclinical Development, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland
200 rdf:type schema:Organization
201 https://www.grid.ac/institutes/grid.418234.8 schema:alternateName Basilea Pharmaceutica (Switzerland)
202 schema:name Basel Institute for Immunology, Basel, Switzerland
203 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...